There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for FBLG is 26.84M and currently, short sellers hold a 8.79% ratio of that float. The average trading volume of FBLG on November 27, 2024 was 401.46K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FBLG) stock’s latest price update
FibroBiologics Inc (NASDAQ: FBLG)’s stock price has gone decline by -13.33 in comparison to its previous close of 2.85, however, the company has experienced a 3.78% increase in its stock price over the last five trading days. globenewswire.com reported 2024-11-19 that HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based therapeutic approach.
FBLG’s Market Performance
FibroBiologics Inc (FBLG) has experienced a 3.78% rise in stock performance for the past week, with a -12.41% drop in the past month, and a 54.38% rise in the past quarter. The volatility ratio for the week is 16.76%, and the volatility levels for the past 30 days are at 14.37% for FBLG. The simple moving average for the past 20 days is -16.06% for FBLG’s stock, with a -62.22% simple moving average for the past 200 days.
Analysts’ Opinion of FBLG
Many brokerage firms have already submitted their reports for FBLG stocks, with H.C. Wainwright repeating the rating for FBLG by listing it as a “Buy.” The predicted price for FBLG in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on October 30, 2024 of the current year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see FBLG reach a price target of $12. The rating they have provided for FBLG stocks is “Buy” according to the report published on September 24th, 2024.
FBLG Trading at -15.39% from the 50-Day Moving Average
After a stumble in the market that brought FBLG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.51% of loss for the given period.
Volatility was left at 14.37%, however, over the last 30 days, the volatility rate increased by 16.76%, as shares sank -10.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.46% lower at present.
During the last 5 trading sessions, FBLG rose by +3.78%, which changed the moving average for the period of 200-days by -66.62% in comparison to the 20-day moving average, which settled at $2.94. In addition, FibroBiologics Inc saw -91.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FBLG starting from O’HEERON PETE, who purchase 8,500 shares at the price of $1.91 back on Aug 12 ’24. After this action, O’HEERON PETE now owns 6,056,647 shares of FibroBiologics Inc, valued at $16,269 using the latest closing price.
Khoja Hamid, the Chief Scientific Officer of FibroBiologics Inc, purchase 10,000 shares at $1.90 during a trade that took place back on Aug 12 ’24, which means that Khoja Hamid is holding 11,250 shares at $19,000 based on the most recent closing price.
Stock Fundamentals for FBLG
The total capital return value is set at -3.3. Equity return is now at value -267.86, with -149.60 for asset returns.
Based on FibroBiologics Inc (FBLG), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -90.69. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -833.73.
Currently, EBITDA for the company is -15.9 million with net debt to EBITDA at 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.23.
Conclusion
In conclusion, FibroBiologics Inc (FBLG) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
